Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eugene Soh

Cardiovascular Disease Manassas, VA Medical Doctor

NPI 1588672000 CMS profile 522291

8100 Ashton Ave Ste 200, Manassas, VA 20109

Open in the dashboard

General payments

$10,746

268 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$31,575 paid to institutions, not to them · program year 2025

Through program year 2025, Eugene Soh of Manassas, VA is reported in the CMS Open Payments database as having received $10,746 across 268 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $31,575 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 82nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,073 57
2024 General $1,213 25
2023 General $1,605 33
2022 General $1,644 35
2021 General $1,648 29
2020 General $306 13
2019 General $2,256 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eugene Soh
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Eugene Soh were reported at $2,073. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Eugene Soh Cardiovascular Disease median Middle half National median
2019 $2,256 $450 $127–$1,392 $163
2020 $306 $242 $77–$751 $114
2021 $1,648 $335 $101–$1,037 $132
2022 $1,644 $395 $121–$1,211 $149
2023 $1,605 $443 $136–$1,283 $160
2024 $1,213 $450 $136–$1,323 $164
2025 $2,073 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cardiovascular Systems Inc. $1,860 61 payments
  2. Boston Scientific Corporation $1,277 24 payments
  3. Novartis Pharmaceuticals Corporation $790 27 payments
  4. Abbott Laboratories $682 9 payments
  5. E.R. Squibb & Sons, L.L.C. $579 9 payments
  6. Janssen Pharmaceuticals, Inc $577 16 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $461 12 payments
  8. Scpharmaceuticals Inc. $412 13 payments
  9. Pfizer Inc. $393 11 payments
  10. Abiomed $360 7 payments
  11. Other $3,354 79 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,738 267 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Coronary Orbital Atherectomy System $702 35 payments
  2. Diamondback Coronary Atherectomy Device $590 15 payments
  3. XARELTO $577 16 payments
  4. Diamondback Coronary Atherectomy Device $524 9 payments
  5. LifeVest $461 12 payments
  6. ENTRESTO $434 14 payments
  7. FUROSCIX $412 13 payments
  8. LEQVIO Cardiology/Vascular Diseases $315 11 payments
  9. CAMZYOS $304 5 payments
  10. LEQVIO Cardiovascular $303 7 payments
  11. Other $6,094 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

2,468

Median for Cardiology: 2,533

Drug cost

$503,969

Median for Cardiology: $485,213

Branded share of claims

23.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 230 $314,839
Entresto Sacubitril/Valsartan Brand 34 $65,406
Xarelto Rivaroxaban Brand 30 $38,776
Farxiga Dapagliflozin Propanediol Brand 19 $24,468
Repatha Sureclick Evolocumab Brand 15 $22,245
Ranolazine Er Ranolazine Brand 34 $6,316
Dofetilide Generic 16 $4,497
Vascepa Icosapent Ethyl Brand 11 $3,831
Metoprolol Succinate Generic 266 $3,503
Atorvastatin Calcium Generic 315 $3,296

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$554,394

Of which drugs: $2,723

Medicare patients

1,263

Average age 77

Services billed

4,709

602 women, 661 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 47%
Heart failure 39%
Atrial fibrillation 39%
Diabetes 37%
Chronic kidney disease 34%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 107 428 $2,723

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FUROSCIX
  • SCPHARMACEUTICALS INC. $163
$163 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $161
$161 — —
VYNDAQEL
  • PFIZER INC. $95
$95 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $22
$22 19 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record